| Filed On | Filing |
|---|---|
| 20 Oct 2026 | EFFECT |
| 20 Oct 2026 | 424B3 |
| 13 Oct 2026 | Proxy statement: special meeting on November 11, 2026 |
| 09 Oct 2026 | S-1 |
| 02 Oct 2026 | PRE 14A |
| 29 Sep 2026 | D |
| 25 Sep 2026 |
8-K: Other Events
As previously disclosed, on November 20, 2025, GT Biopharma, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its commo... |
| 21 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
THIS FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this “Amendment”), dated as of September 18, 2026, is entered into among GT Biopharma, Inc., a Delaware corporation (the “Company”) and each Person identified on the signature pages ... |
| 15 Sep 2026 | SCHEDULE 13G |
| 15 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This Securities Purchase Agreement (this “Agreement”) is dated as of September 14, 2026, between GT Biopharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its... |
| 03 Sep 2026 | 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more |
| 14 Aug 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 14 Aug 2026 | 10-Q |
| 02 Jul 2026 |
Proxy statement: annual meeting on August 14, 2026
CEO pay $1.7M, up 46% · say-on-pay vote |
| 18 Jun 2026 | PRE 14A |
| 12 Jun 2026 | 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year |
| 22 May 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 15 May 2026 | 10-Q |
| 13 May 2026 | EFFECT |
| 13 May 2026 | 424B3 |
Loading...
